Summit Therapeutics (SMMT) Stock Price & Analysis

SMMT$15.07-1.56 -9.41%
BiotechnologyLarge CapGrowth Stock
Compare
Market cap$12.03BEnterprise value$12.77BRevenue (TTM)$0Market positionTop 25%

Score

67
Bullish
Value
53
Quality
47
Growth
100

AI Analysis

Snapshot

Summit Therapeutics is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 67/100) in Biotechnology. Under the hood: revenue compounding ~-100% annually over recent years. Street targets still imply ~113% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

53
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

47
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Summit Therapeutics Inc. (SMMT) last printed $15.07. Equity value is $12.03B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$2.38M$14.17M$57.09M$611,872.00$628,875.00$1.34M$583,190.00$0.00$0.00$0.00

About

Summit Therapeutics Inc. is a biopharmaceutical company developing ivonescimab, an investigational bispecific antibody designed to block PD-1 and VEGF, for non-small cell lung cancer and colorectal cancer. Summit licensed the antibody from Akeso and is running Phase 3 trials in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa. The company is based in Miami, Florida.

Summit Therapeutics (SMMT) Stock Price & Analysis

SMMT price $15.07 -1.56 -9.41%

Ticker
SMMT
Price
$15.07
Change
-1.56 -9.41%
Market cap
$12.03B
Forward P/E
128.10
Dividend yield
0.00%
Beta
-1.24
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
67
Value
53
Quality
47
Growth
100

Stocklytics score rationale: value 53, quality 47, growth 100.

AI Score 25. Summit Therapeutics Inc. has a market cap of $12.79 billion but is currently unprofitable with a net income margin of 0 and a price-to-earnings ratio of -14.3

Fair value

SMMT fair value $11.87. Price $15.07. Price is 27% above fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value blends a 10-year DCF and an earnings multiple: the average of the DCF value and an earnings value from next-twelve-months EPS times 28.5, a blend of the industry median and the stock's own 10-year median. How we calculate it →

Compare SMMT

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-03-18—-0.30—3.31M
2027-02-22—-0.36—3.31M
2026-11-04-0.26-0.28—111.11K
2026-07-23-0.28-0.27—113.89K
2026-04-30-0.24-0.33—54.42K
2026-02-23-0.29-0.10—56.78M
2025-10-20-0.31-0.18—76.50M
2025-08-11-0.76-0.09——
2025-05-01-0.09-0.09——
2025-02-24-0.08-0.08——
2024-10-30-0.08-0.07——
2024-08-06-0.05-0.06——
2024-05-01-0.06-0.06——
2024-02-20-0.042.09—12.31M
2023-11-07-0.03———
2023-08-09-0.02———
2023-05-11-0.06———
2023-03-09-0.07-0.265.00K—
2022-11-09-0.14-0.26220.00K—
2022-08-11-0.17-0.27235.00K—
2022-05-11-0.22-0.28250.00K—
2022-03-17-0.28-0.27251.00K4.45M
2021-11-15-0.20-0.29971.41K1.71M
2021-08-11-0.27-0.1841.21K57.00K
2021-05-17-1.05-0.24139.28K4.08M
2021-03-17-0.90-0.09135.28K4.00M
2020-11-16-1.24-0.01140.28K19.87M
2020-09-29-1.15-0.02137.20K5.13M
2020-06-03-0.10-0.03260.60K5.13M
2019-12-31-0.19—11.73K—
2019-12-17-0.22-0.40120.36K218.83K
2019-10-11-0.20-0.56122.84K—
2019-06-26-0.20-0.164.95M—
2019-03-27-0.35-0.241.04M693.39K
2018-12-11-0.65-0.31857.77K693.39K
2018-09-202.12-0.3749.86M346.83M
2018-06-05-0.52-0.755.33M6.97M
2018-04-13-0.16-0.864.39M3.40M
2017-12-06-0.20-0.583.30M3.40M
2017-08-311.100.354.75M28.47M

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-10-08Anand BhaskarBuy100.00K——
2026-06-12Zanganeh MahkamBuy3.81M$13.1249.99M
2026-06-12DUGGAN ROBERT WBuy3.81M$13.1249.99M
2026-06-04DUGGAN ROBERT WBuy100.00K$14.601.46M
2026-06-04Zanganeh MahkamBuy100.00K$14.601.46M
2026-06-04Soni Manmeet SinghBuy25.00K$14.43360.75K
2026-06-04Soni Manmeet SinghBuy25.00K$14.46361.50K
2026-01-08Anand BhaskarBuy30.00K$18.83564.90K
2026-01-02Zanganeh MahkamBuy11.23K$17.52196.78K
2026-01-02DUGGAN ROBERT WBuy11.23K$17.52196.78K
2026-01-02Booth Robert F.Buy35.00K$17.52613.20K
2026-01-02Booth Robert F.Buy7.18K$17.52125.79K
2026-01-02Xia YuBuy35.00K$17.52613.20K
2026-01-02Huber JeffBuy35.00K$17.52613.20K
2026-01-02Huber JeffBuy9.88K$17.52173.19K
2026-01-02Ronaghi MostafaBuy35.00K$17.52613.20K
2026-01-02Clark Kenneth ABuy35.00K$17.52613.20K
2026-01-02Clark Kenneth ABuy17.80K$17.52311.79K
2026-01-02Cesano AlessandraBuy35.00K$17.52613.20K
2026-01-02Cesano AlessandraBuy3.22K$17.5256.40K
2025-10-21Xia YuBuy533.62K$18.7410.00M
2025-10-21Anand BhaskarBuy26.68K$18.74499.98K
2025-10-21Soni Manmeet SinghBuy53.36K$18.74999.99K
2025-10-21DUGGAN ROBERT WBuy13.98M$18.74262.00M
2025-10-21DUGGAN ROBERT WBuy266.81K$18.745.00M
2025-10-21DUGGAN ROBERT WBuy26.68K$18.74499.98K
2025-10-21Zanganeh MahkamBuy13.98M$18.74262.00M
2025-10-21Zanganeh MahkamBuy266.81K$18.745.00M
2025-10-21Zanganeh MahkamBuy26.68K$18.74499.98K
2025-09-18Anand BhaskarBuy50.00K$19.23961.50K
2025-09-11Zanganeh MahkamBuy5.00K$18.0790.35K
2025-09-11DUGGAN ROBERT WBuy5.00K$18.0790.35K
2025-09-10Zanganeh MahkamBuy333.39K$17.685.89M
2025-09-10DUGGAN ROBERT WBuy333.39K$17.685.89M
2025-05-30Zanganeh MahkamBuy74.55K$2.64196.80K
2025-05-30Zanganeh MahkamSell74.55K$2.64196.80K
2025-05-30DUGGAN ROBERT WBuy74.55K$2.64196.80K
2025-05-30DUGGAN ROBERT WSell74.55K$2.64196.80K
2025-04-29Anand BhaskarBuy600.00K$3.852.31M
2025-04-29Anand BhaskarBuy75.00K$17.851.34M
2025-04-29Soni Manmeet SinghBuy11.20M$1.6818.82M
2025-04-29DUGGAN ROBERT WBuy9.59M$1.6816.11M
2025-04-29DUGGAN ROBERT WBuy1.04M$1.061.10M
2025-04-29DUGGAN ROBERT WBuy400.00K$1.29516.00K
2025-04-29Zanganeh MahkamBuy9.59M$1.6816.11M
2025-04-29Zanganeh MahkamBuy1.04M$1.061.10M
2025-04-29Zanganeh MahkamBuy400.00K$1.29516.00K
2025-04-08Zanganeh MahkamBuy3.99M$1.586.30M
2025-04-08Zanganeh MahkamBuy3.99M$1.586.30M
2025-04-08DUGGAN ROBERT WBuy3.99M$1.586.30M
2025-04-08DUGGAN ROBERT WBuy3.99M$1.586.30M
2025-01-12Anand BhaskarBuy75.00K$17.851.34M
2025-01-02DUGGAN ROBERT WBuy10.72K$18.35196.79K
2025-01-02Zanganeh MahkamBuy10.72K$18.35196.79K
2025-01-02Huber JeffBuy35.00K$18.35642.25K
2025-01-02Xia YuBuy35.00K$18.35642.25K
2025-01-02Xia YuBuy5.44K$18.3599.79K
2025-01-02Cesano AlessandraBuy35.00K$18.35642.25K
2025-01-02Cesano AlessandraBuy3.07K$18.3556.39K
2025-01-02Ronaghi MostafaBuy35.00K$18.35642.25K
2025-01-02Clark Kenneth ABuy35.00K$18.35642.25K
2025-01-02Clark Kenneth ABuy16.99K$18.35311.78K
2025-01-02Booth Robert F.Buy35.00K$18.35642.25K
2025-01-02Booth Robert F.Buy6.86K$18.35125.79K
2024-10-11Clark Kenneth ABuy200.00K$19.953.99M
2024-10-03Zanganeh MahkamBuy315.68K$1.58498.78K
2024-10-03Zanganeh MahkamSell315.68K$1.58498.78K
2024-09-11Zanganeh MahkamBuy44.05K$22.70999.98K
2024-09-11DUGGAN ROBERT WBuy3.33M$22.7075.50M
2024-09-11Huber JeffBuy44.05K$22.70999.98K
2024-09-11Soni Manmeet SinghBuy44.05K$22.70999.98K
2024-09-11Anand BhaskarBuy22.03K$22.70499.99K
2024-08-23Soni Manmeet SinghBuy2.80M$1.684.70M
2024-08-23Zanganeh MahkamBuy2.40M$1.684.03M
2024-08-23Zanganeh MahkamBuy260.00K$1.06275.60K
2024-08-23Zanganeh MahkamBuy100.00K$1.29129.00K
2024-06-27Huber JeffBuy17.88K$7.87140.74K
2024-06-27Huber JeffBuy200.00K$7.871.57M
2024-06-27Huber JeffOther0——
2024-04-11Ronaghi MostafaBuy25.32K$4.03102.02K
2024-04-11Ronaghi MostafaBuy200.00K$4.03806.00K
2024-04-11Ronaghi MostafaOther0——
2024-04-02Soni Manmeet SinghBuy1.10M$3.854.24M
2024-04-02Anand BhaskarBuy600.00K$3.852.31M
2024-04-02Anand BhaskarOther0——
2024-03-27Zanganeh MahkamBuy34.32K$3.72127.67K
2024-03-27Zanganeh MahkamBuy26.00K$3.7296.72K
2024-03-27Zanganeh MahkamBuy20.00K$3.7174.20K
2024-03-26Zanganeh MahkamBuy30.00K$3.75112.50K
2024-03-26Dhingra AnkurBuy100.00K$3.75375.00K
2024-01-02Cesano AlessandraBuy21.36K$2.6456.40K
2024-01-02Cesano AlessandraBuy35.00K$2.6492.40K
2024-01-02Booth Robert F.Buy47.65K$2.64125.80K
2024-01-02Booth Robert F.Buy35.00K$2.6492.40K
2024-01-02Clark Kenneth ABuy70.49K$2.64186.10K
2024-01-02Clark Kenneth ABuy35.00K$2.6492.40K
2024-01-02Mahatme UjwalaBuy52.58K$2.64138.80K
2023-12-31Xia YuOther0——
2023-03-07Xia YuBuy21.52M$1.0522.60M
2023-01-17Xia YuBuy10.00M$2.5125.10M

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 269, holders +29 vs prior quarter. Ownership 17.65%.

HolderSharesChangeChange %Value
BAKER BROS. ADVISORS LP32.79M-3.60M-9.91%477.70M
FMR LLC10.04M-809.25K-7.46%146.34M
STATE STREET CORP9.54M2.51M+35.69%138.95M
BLACKROCK, INC.9.53M-124.72K-1.29%138.84M
VANGUARD CAPITAL MANAGEMENT LLC5.73M22.68K+0.40%83.55M
UBS GROUP AG5.23M1.55M+42.21%76.26M
VANGUARD PORTFOLIO MANAGEMENT LLC5.04M-191.06K-3.65%73.46M
GOLDMAN SACHS GROUP INC4.51M4.20M+1352.52%65.76M
PRICE T ROWE ASSOCIATES INC /MD/3.89M-4.38M-52.96%56.73M
POINT72 ASSET MANAGEMENT, L.P.3.70M2.91M+371.55%53.88M
GEODE CAPITAL MANAGEMENT, LLC3.43M111.41K+3.36%49.95M
MILLENNIUM MANAGEMENT LLC2.35M2.35MNew34.23M
ADAGE CAPITAL PARTNERS GP, L.L.C.1.99M1.99MNew28.99M
BALYASNY ASSET MANAGEMENT L.P.1.90M1.36M+247.28%27.74M
CITADEL ADVISORS LLC1.73M1.28M+290.66%25.14M
ABERDEEN GROUP PLC1.69M1.03M+154.54%24.68M
SQUAREPOINT OPS LLC1.59M976.86K+159.13%23.18M
MORGAN STANLEY1.45M-200.57K-12.15%21.13M
NORGES BANK1.38M1.38MNew20.14M
LOGOS GLOBAL MANAGEMENT LP1.35M1.35MNew19.67M
OCTAGON CAPITAL ADVISORS LP1.25M1.25MNew18.21M
D. E. SHAW & CO., INC.1.24M-998.67K-44.54%18.12M
KYNAM CAPITAL MANAGEMENT, LP1.20M1.20MNew17.48M
PICTET ASSET MANAGEMENT HOLDING SA1.13M-188.88K-14.27%16.43M
SUSQUEHANNA INTERNATIONAL GROUP, LLP1.11M541.70K+95.45%16.16M

Insights · Forecast · Financials · Learn

Stocklytics home · Screener